Experimental and emerging therapies for chronic hepatitis C virus infection

Expert Opinion on Investigational Drugs

Volumn 10, Issue 8, 2001, Pages 1457-1469

  Zein, N N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatitis C; Interferons; Ribavirin; Therapy

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON; AMANTADINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CONSENSUS INTERFERON; CYTOKINE; ENZYME INHIBITOR; HELICASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBOZYME; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANEMIA; CHEMICAL MODIFICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; ECONOMIC ASPECT; ERADICATION THERAPY; EXPERIMENT; HEPATITIS C; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; RIBAVIRIN; RNA, VIRAL;

EID: 0034905446     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.8.1457     Document Type: Review

References (119)

1. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
2. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
3. A proposed system for the nomenclature of hepatitis C viral genotypes
4. Clinical significance of hepatitis C virus genotypes
5. Virus interference. I. The interferon
6. Biological basis for the clinical use of interferon
7. Interferon and other therapies for hepatitis B and hepatitis C infections
8. Interferon-alpha for viral hepatitis
9. Biochemistry of interferons and their actions
10. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus
11. Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon
12. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine
13. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b
14. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy
15. Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon
16. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report
17. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: Interim results of a randomized controlled open study
18. Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia
19. Treatment of chronic non-A non-B hepatitis with human interferon beta: A preliminary study
20. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis
21. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
22. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
23. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies
24. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
25. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial
26. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis
27. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis
28. Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: Application of a numerical scoring system for evaluating sequential morphologic changes
29. Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: Second report
30. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
31. Interferon therapy in hepatitis C
32. Interferons in the management of viral hepatitis
33. Molecular mechanisms of action of ribavirin
34. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response
35. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
36. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis
37. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
38. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
39. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
40. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
41. Available options for treatment of interferon nonresponders
42. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers
43. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
44. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C
45. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy
46. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
47. Principles of interferon induction therapy
48. Re-treatment of chronic hepatitis C with consensus interferon
49. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: A randomized prospective trial
50. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
51. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
52. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments
53. Amantadine for influenza A
54. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
55. Dose-dependent acute clearance of hepatitis C geno type 1 virus with interferon alfa
56. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
57. Peginterferon alfa-2a in patients with chronic hepatitis C
58. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
59. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a Phase III, randomized, actively-controlled, multicenter study
60. Pegylated interferon and ribavirin for the treatment of HCV infected patients who failed previous interferon therapy
61. Processing pathways of the hepatitis C virus proteins
62. NS3 is a serine protease required for processing of hepatitis C virus polyprotein
63. Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3
64. Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro
65. In vitro study of the NS2-3 protease of hepatitis C virus
66. Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: Implications for development of antiviral agents and vaccines
67. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A
68. Molecular model of the specificity pocket of the hepatitis C virus protease: Implications for substrate recognition
69. Substrate specificity of the hepatitis C virus serine protease NS3
70. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides
71. Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli
72. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus
73. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity
74. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site
75. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
76. Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets
77. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expresse in Escherichia coli
78. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus
79. Internal ribosome entry site within hepatitis C virus RNA
80. Therapy and clinical trials
81. The chemistry of self-splicing RNA and RNA enzymes
82. A small catalytic oligoribonucleotide
83. Ribozymes: Structure, characteristics and use as potential antiviral agents
84. The use of antisense and other molecular approaches to therapy of chronic viral hepatitis
85. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes
86. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice
87. A potential therapeutic application of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection
88. Antisense has growing pains
89. A hitchhiker's guide to antisense and nonantisense biochemical pathways
90. A good antisense molecule is hard to find
91. Antisense treatment of viral infection
92. Hepatitis C virus replication during acute infection in the chimpanzee
93. Detection of widespread hepatocyte infection in chronic hepatitis C
94. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: Reevaluation of the role of HCV in liver disease
95. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
96. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures
97. Binding of hepatitis C virus to CD81
98. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
99. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
100. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees-trials of experimental immune treatment
101. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
102. A single peripheral CD8+ T cell can give rise to progeny expressing *type 1 and/or *type 2 cytokine genes and can retain its multipotentiality through many cell divisions
103. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
104. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
105. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections
106. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
107. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection
108. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C
109. Aerosol liposomal interleukin-2 (aIL-2) combined with interferon alpha-2b/ribavirin (IFN/R) as a novel approach in chronic hepatitis C (HCV) patients who failed previous IFN/R treatment: A preliminary report
110. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus
111. A Phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C
112. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
113. Humoral immunity in acute and chronic hepatitis C infection
114. Vaccine development for hepatitis C
115. Persistence of HCV despite antibodies to both putative envelope glycoproteins
116. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection
117. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
118. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons